

ASX ANNOUNCEMENT
30 November 2021

**AUSTRALIA'S FIRST mRNA COVID-19 VACCINE CANDIDATE
SUCCESSFULLY MANUFACTURED**

IDT Australia Limited (ASX: IDT) provides the following market update.

As previously announced on 13 October 2021, IDT entered into a Master Services Agreement and Services Order with Monash Institute of Pharmaceutical Sciences (MIPS) to provide cGMP manufacturing services to produce drug product for MIPS' mRNA COVID-19 receptor binding domain vaccine clinical trial.

IDT today announces successful manufacture of the mRNA Drug Product. The Drug Product has met all specifications and is now progressing through the release process to be supplied to MIPS for use in their upcoming clinical trial. Successful manufacture signifies the completion of the material elements of the Master Services Agreement and Services Order, with ongoing product stability testing the only remaining item.

See link to the Victorian Government Press:

<https://www.premier.vic.gov.au/victoria-makes-australias-first-mrna-vaccine-candidate>

Ends.../


IDT

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

Ancila Desai

Company Secretary / CFO - IDT Australia Limited

+61 3 9801 8888

A decorative graphic in the bottom right corner consisting of overlapping, semi-transparent geometric shapes in shades of green and blue, resembling a stylized ribbon or abstract design.